HCP1105

HCP1105 is a small molecule drug developed by Hanmi Pharmaceutical for the treatment of complex dyslipidemia and other lipid disorders. It acts as an inhibitor of HMG-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, making it part of the statin class. The drug has been investigated primarily for cardiovascular and metabolic diseases, including hyperlipidemia and coronary disease. Clinical trials have evaluated its efficacy and safety in patients with combined hyperlipidemia at high risk for coronary heart disease[1][4][7]. As of March 2025, its highest global R&D status is "Pending," with some studies reaching Phase 3[1].